Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

AStrokeOfLuck Feb. 21 at 3:48 PM

$XBI $AMGN $BIIB $LABU $PILL

1 · Reply

CharlieeMungerTWITS Feb. 21 at 1:17 AM

$BIIB we buying this pig for Alzheimer’s indication pdufa ?!

0 · Reply

erevnon Feb. 20 at 3:40 PM

Barclays initiates coverage on Biogen $BIIB at Equal-Weight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

RenkoTradingSystem Feb. 19 at 8:37 PM

$BIIB Weekly 1% Renko Chart Two Red Bricks on the Weekly chart. I sold my 1/2 position. Loss: 1.5% I wouldn't buy BIIB again until there is a Green Brick on the Weekly chart. ENTRY CHECKLIST The Setup BOTH #1 and #2 MUST PASS 1. Weekly SPY Chart has a Green Brick. PASS 2. Weekly BIIB Chart has a Green Brick. FAIL ALL MUST PASS 195 MIN 1% Renko Chart: > SCTR > 70-80 (80+ Strong) > Stock Price is above EMA(20) and is rising. > Pullback had at least 2-3 Red Bricks (clean, not choppy). > RSI(14): Between 40 and 70. >StochRSI: Under 0.20 during the pullback.

0 · Reply

RenkoTradingSystem Feb. 19 at 4:16 PM

$BIIB 190 MIN 1% Renko Chart One Red Brick has printed. The bottom of the Red Brick is $192.91 Current Price: $192.05 I have a 1/2 position on the 2nd Green Brick. That means I'm selling on the 1st Red Brick tomorrow if the price is below the bottom of the red Brick at $192.91. It will be about a 1.6% loss.

0 · Reply

Gabrielis Feb. 17 at 2:09 PM

$BIIB 196 dead pre, I’m flat, not chasing inside the range

0 · Reply

RenkoTradingSystem Feb. 15 at 12:04 PM

$BIIB did not complete the third Green brick last week and went back to two Green Bricks. I took a 1/2 position on the second Green Brick. I will take a second 1/2 position if and when the third Green Brick is competed provided this happens... Third Green Brick (Rare, Defensive Entry) Allowed ½ position only if ALL are true: Pullback was 4+ red bricks (BIIB - 4) OK RSI below 65 - (BIIB 63.56) This will probably go higher StochRSI recently crossed (not extended) -- Wait and see Market trend very strong -- Wait and see Otherwise → stand down. I'll wait for the third Green Brick but I'm pretty sure the RSI will be too high.

0 · Reply

RenkoTradingSystem Feb. 13 at 3:48 PM

$BIIB completed a third Green Brick so I went long with a 1/2 position since I missed the first Green Brick. I will sell when the first Red Brick is completed. All the stop-losses I use are set for -2% of the stock value which would result in a Red Brick being displaced. Possible to have a larger loss than 2% if the stock gaps down or has a big move down at the open.

0 · Reply

RenkoTradingSystem Feb. 13 at 10:59 AM

$BIIB Since BIIB now has two Green Bricks it only qualifies for a half position when a third Green Brick completes.

1 · Reply

RenkoTradingSystem Feb. 12 at 4:39 PM

$BIIB Daily Renko Brick Size: 1% of the price: 1.94 RSI: 59.89 (Bullish) StochRSI: 0.209 (Breakout) BIIB has one Green Brick after a Red Brick and it is above the StochRSI 0.20 which is a Buy Signal. A long position can be taken before the close today if the Brick has completed. Otherwise I'd wait for tomorrow. First Green Brick: 1/2 position Second Green Brick: The other 1/2 position First Red Brick: Sell 1/2 your position. Second Red brick: Close the position. Biogen (BIIB) reported its Q4 and full-year 2025 earnings on February 6, 2026, with results that beat analyst expectations despite a year-over-year decline in total revenue. The company saw strong performance from new product launches (Leqembi, Skyclarys) which helped offset declining revenue from its legacy multiple sclerosis (MS) portfolio.

0 · Reply

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 11, 2026, 5:00 PM EST - 11 days ago

Biogen Announces Board Chair Transition

Feb 9, 2026, 8:36 AM EST - 14 days ago

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Feb 9, 2026, 6:49 AM EST - 14 days ago

Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise

Feb 6, 2026, 2:14 PM EST - 17 days ago

Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript

Feb 6, 2026, 8:59 AM EST - 17 days ago

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Feb 6, 2026, 7:35 AM EST - 17 days ago

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Feb 6, 2026, 6:10 AM EST - 17 days ago

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Feb 4, 2026, 7:30 AM EST - 19 days ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Jan 28, 2026, 7:30 AM EST - 26 days ago

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Jan 25, 2026, 6:30 PM EST - 4 weeks ago

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Jan 13, 2026, 8:48 AM EST - 5 weeks ago

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Jan 12, 2026, 7:45 PM EST - 5 weeks ago

Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:05 AM EST - 6 weeks ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Jan 11, 2026, 2:00 PM EST - 6 weeks ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Jan 5, 2026, 8:00 PM EST - 6 weeks ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Dec 30, 2025, 8:57 AM EST - 7 weeks ago

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

Dec 22, 2025, 11:20 AM EST - 2 months ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 9, 2025, 7:00 AM EST - 2 months ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 8, 2025, 6:30 PM EST - 2 months ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 5, 2025, 9:00 AM EST - 2 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Dec 5, 2025, 9:00 AM EST - 2 months ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 3, 2025, 2:03 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:40 PM EST - 2 months ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 3:43 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:30 AM EST - 3 months ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 3 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Nov 27, 2025, 7:30 PM EST - 3 months ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 25, 2025, 7:30 AM EST - 3 months ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 24, 2025, 11:17 AM EST - 3 months ago

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Nov 24, 2025, 7:30 AM EST - 3 months ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 3 months ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:25 AM EST - 3 months ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

Nov 21, 2025, 1:13 PM EST - 3 months ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

Nov 20, 2025, 7:30 AM EST - 3 months ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference

Nov 18, 2025, 8:25 AM EST - 3 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD GSK JNJ LLY

Nov 17, 2025, 7:30 AM EST - 3 months ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Nov 17, 2025, 7:30 AM EST - 3 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

STOK

Nov 17, 2025, 6:00 AM EST - 3 months ago

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Nov 14, 2025, 4:05 PM EST - 3 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS

Nov 13, 2025, 6:41 PM EST - 3 months ago

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

Nov 13, 2025, 6:30 PM EST - 3 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Nov 10, 2025, 5:01 PM EST - 3 months ago

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Nov 3, 2025, 7:30 AM EST - 4 months ago

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oct 30, 2025, 9:16 PM EDT - 4 months ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:40 AM EDT - 4 months ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 6:11 AM EDT - 4 months ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 26, 2025, 7:30 PM EDT - 4 months ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 24, 2025, 8:30 AM EDT - 4 months ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 7:30 AM EDT - 4 months ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

AStrokeOfLuck Feb. 21 at 3:48 PM

$XBI $AMGN $BIIB $LABU $PILL

1 · Reply

CharlieeMungerTWITS Feb. 21 at 1:17 AM

$BIIB we buying this pig for Alzheimer’s indication pdufa ?!

0 · Reply

erevnon Feb. 20 at 3:40 PM

Barclays initiates coverage on Biogen $BIIB at Equal-Weight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

RenkoTradingSystem Feb. 19 at 8:37 PM

0 · Reply

RenkoTradingSystem Feb. 19 at 4:16 PM

0 · Reply

Gabrielis Feb. 17 at 2:09 PM

$BIIB 196 dead pre, I’m flat, not chasing inside the range

0 · Reply

RenkoTradingSystem Feb. 15 at 12:04 PM

0 · Reply

RenkoTradingSystem Feb. 13 at 3:48 PM

0 · Reply

RenkoTradingSystem Feb. 13 at 10:59 AM

$BIIB Since BIIB now has two Green Bricks it only qualifies for a half position when a third Green Brick completes.

1 · Reply

RenkoTradingSystem Feb. 12 at 4:39 PM

0 · Reply

The_Alpha_Male Feb. 10 at 10:00 PM

$BIIB Undervalued?

1 · Reply

erevnon Feb. 10 at 2:54 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OptionRunners Feb. 9 at 8:18 PM

$BIIB call buyer

0 · Reply

erevnon Feb. 9 at 6:03 PM

RBC Capital maintains Biogen $BIIB at Outperform and raises the price target from $217 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 3:49 PM

Wells Fargo maintains Biogen $BIIB at Equal-Weight and raises the price target from $190 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 2:44 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

mikesterz7 Feb. 9 at 1:22 PM

$BIIB Analyst price targets for BIIB are in the range of $190 to $215, implying a downside of about 6% to an upside of nearly 7% from the last close.

0 · Reply

John_Wick1234 Feb. 9 at 12:25 PM

$BIIB Nice Double Bottom with good Volume.

0 · Reply

erevnon Feb. 9 at 11:52 AM

Piper Sandler maintains Biogen $BIIB at Neutral and raises the price target from $157 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

anachartanalyst Feb. 9 at 11:01 AM

$BIIB https://anachart.com/wp-content/uploads/ana_temp/1770634874_soc-img.jpg

0 · Reply

StocktwitsNews Feb. 9 at 4:14 AM

Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi $BIIB https://stocktwits.com/news/equity/markets/biogen-stock-to-pop-again-china-fast-tracks-at-home-alzheimers-drug-leqembi/cZbHVi7R48i

0 · Reply

Whiskey1679 Feb. 8 at 11:19 PM

Whiskey's Penny Picks out early tomorrow morning! Movers & Shakers: $CHR.X $BIIB $ASTER.X $CC.X $JYAI.X

0 · Reply

Market Cap	28.18B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	12.56
Forward PE	12.20
Profit Margin	13.07%
Debt to Equity Ratio	0.34

Volume	871,338
Avg Vol	1,881,030
Day's Range	N/A - N/A
Shares Out	146.76M
Stochastic %K	35%
Beta	0.16
Analysts	Sell
Price Target	$206.53